- The Wall Street Journal investigative reporter John Carreyrou knew from his first phone call with a Theranos insider that he had a great story.
- Comparing interview accounts and past coverage of Theranos’ founder, Elizabeth Holmes, Carreyrou discovered major discrepancies.
- Carreyrou said Holmes had been lying not only to the public but to her own board.
- On Tuesday, Carreyrou reported that Theranos plans to shut down.
John Carreyrou knew he had a story on his hands the moment his first phone call ended with Alan Beam, a former laboratory director at Theranos.
Carreyrou in early 2015 had just finished the story “Medicare Unmasked” for The Wall Street Journal and was looking for a new project to work on. Theranos was a healthcare tech company that had become a startup sweetheart in both the media and Silicon Valley.
“In terms of both the battle we had to wage and how multifaceted, colourful, and sheer entertaining the story has been, this has probably been the best,” Carreyrou told Business Insider in May. His first in a series of detailed exposés about the company was published on the front page of The Wall Street Journal in October 2015. In his new book, “Bad Blood: Secrets and Lies in a Silicon Valley Startup,” Carreyrou reveals more to the story beyond The Journal’s coverage.
Carreyrou first caught wind of scepticism around Theranos back in early 2015, when Adam Clapper, a pathologist who ran an industry blog, first approached Carreyrou about Theranos.
Clapper’s tip and a handful of secondhand sources helped confirm Carreyrou’s gut feeling when he read a New Yorker profile on Theranos: Something was off. But Carreyrou knew that to push the story forward he’d need to talk to someone with firsthand experience at the company.
From that point, it took him about 2 1/2 weeks to make his first contact with Beam (a pseudonym). After one phone call, Carreyrou knew he had a great story on his hands. Beam told Carreyrou everything he knew about the company. The offenses he said he witnessed included cheating on proficiency tests for the technology and providing false data to patients.
“He was the biggest hero of the story, but he was also a very reluctant hero,” Carreyrou said. By speaking with Carreyrou, Beam subjected himself to speculation and relentless harassment from Theranos.
After Beam’s recount, Carreyrou went back and reread past coverage on Theranos and Holmes. The lack of peer-reviewed data to back up the company’s scientific claims, Holmes’ vague descriptions about how Theranos’ blood-testing technology worked, and the secrecy that shrouded day-to-day operations at the company stood out to Carreyrou.
It became clear to him that there was a discrepancy between what Holmes portrayed to the public and the reality, and he said that discrepancy was perpetuated through lies, including one regarding the nature of her relationship with Sunny Balwani – a company executive and Holmes confidant – to the board of Theranos.
Once Carreyrou started speaking with Beam, the story unravelled quickly. From there, he was able to reach many other ex-employee sources. Beam, along with a lot of the former employees, seemed traumatized by working at Theranos.
“It was like a mind-warping sort of experience,” Carreyrou told Business Insider.
Carreyrou reported Tuesday that Theranos, which at one point was valued at $US9 billion, told investors that it was shutting down.
This article was initially published on May 21 and has been updated.
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.